INCREASED THROMBOEMBOLIC RISK OF JAK INHIBITORS AFTER SWITCHING FROM BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Eun, Y. [1 ]
Seo, G. H. [2 ]
Kang, S. Y. [3 ]
Lee, S. [3 ]
Kim, H. [3 ,4 ]
Cha, H. S. [3 ]
Koh, E. M. [3 ]
Lee, J. [3 ]
机构：
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Med, Sch Med, Seoul, South Korea
[2] Hlth Insurance Review & Assessment Serv, Wonju, South Korea
[3] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South Korea
[4] Sungkyunkwan Univ, Dept Med Humanities, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.4952
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0418
引用
收藏
页码：1337 / 1337
页数：1
相关论文
共 50 条
  • [1] Drug Survival of JAK Inhibitors and Biologic DMARDs in Rheumatoid Arthritis Patients
    Chow, Jocelyn
    Sraka, Gabrielle
    Chau, Kristie
    Soucy, Elaine
    Chow, Andrew
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 797 - 798
  • [2] SURVIVAL ANALYSIS OF BIOLOGICAL DMARDS AND JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS REQUIRING SWITCHING OF TREATMENT
    Bobkova, A. O.
    Glukhova, S. I.
    Karateev, A. E.
    Potapova, A. S.
    Lila, A. M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S149 - S150
  • [3] Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
    Miyazaki, Yusuke
    Nakayamada, Shingo
    Tanaka, Hiroaki
    Hanami, Kentaro
    Fukuyo, Shunsuke
    Kubo, Satoshi
    Yamaguchi, Ayako
    Miyagawa, Ippei
    Satoh-Kanda, Yurie
    Todoroki, Yasuyuki
    Inoue, Yoshino
    Ueno, Masanobu
    Tanaka, Yoshiya
    RMD OPEN, 2025, 11 (01):
  • [4] Cancer risk with biologic DMARDs in rheumatoid arthritis
    Reactions Weekly, 2017, 1672 (1) : 11 - 11
  • [5] Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors
    Meyer, Anja
    Wittekind, Paula S.
    Kotschenreuther, Konstantin
    Schiller, Joanna
    von Tresckow, Julia
    Haak, Thomas H.
    Kofler, David M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (12)
  • [6] The Increased Risk of Thromboembolic Events in Patients with Rheumatoid Arthritis
    Aranega Gonzalez, Raquel
    Juanola Pla, Jordi
    Falga Tirado, Concepcion
    Lopera Marmol, Carlos
    Ortega Castillo, Pilar
    Ruzafa, Lafont
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (01) : 160 - 160
  • [7] DRUG PERSISTENCE ON JANUS KINASE (JAK) INHIBITORS COMPARED TO BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE STUDY IN THE AUSTRALIAN POPULATION
    Scheepers, Lieke
    Jones, Graeme
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 21 - 21
  • [8] Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
    Maro, Judith
    Menzin, Talia
    Hornbuckle, Kenneth
    Giles, Jon T.
    Kavanaugh, Arthur
    Doerner, Thomas
    Martin, David
    Huang, Jane
    Salinas, Claudia A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [9] DRUG PERSISTENCE ON JANUS KINASE (JAK) INHIBITORS COMPARED TO BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE STUDY IN THE AUSTRALIAN POPULATION
    Scheepers, L.
    Jones, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1335 - 1335
  • [10] RISK OF VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC AND NON-BIOLOGIC DMARDS
    Maro, J. C.
    Menzin, T.
    Hornbuckle, K.
    Giles, J. T.
    Kavanaugh, A.
    Doerner, T.
    Martin, D.
    Huang, T.
    Salinas, C. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 932 - 932
12345